GTAM
CRSP icon

Global Trust Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Global Trust Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$7.87K – 479
2024
Q4 		$7.87K Sell
200
-300
-60% -$14.2K ﹤0.01% 416
2024
Q3 		$23.5K Hold
500
– – 0.01% 330
2024
Q2 		$27K Buy
500
+300
+150% +$17.4K 0.01% 300
2024
Q1 		$13.6K Buy
+200
New +$14.3K 0.01% 343

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Global Trust Asset Management's CRSP Position: Q1 2025 in Review

Global Trust Asset Management sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 200 shares — an estimated $7.87K sold.

Global Trust Asset Management first reported a position in CRSP in Q1 2024 and held it in 4 quarters. The position peaked at $27K in Q2 2024. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Global Trust Asset Management reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Global Trust Asset Management sold 200 CRISPR Therapeutics shares in Q1 2025, an estimated $7.87K.
  • Global Trust Asset Management first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 4 quarters.
  • Global Trust Asset Management's CRISPR Therapeutics position peaked at $27K in Q2 2024.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Global Trust Asset Management's 13F filing for Q1 2025, filed 18 Apr 2025.